Stock · Healthcare
ABT Abbott Laboratories
Abbott Laboratories has a solid dividend profile with no major red flags in the snapshot data.
Why we rate it 6.8
- Yield of 2.39% is in the typical sustainable zone (2-4%)
- Payout ratio of 79% is on the higher side — leaves less buffer for earnings volatility
- Current yield is meaningfully above the 5-year average of 1.82% — could be a value opportunity or a stress signal
- Large-cap scale (>$50B) — established business with predictable cash flows
Where ABT ranks
We compute the same 0–10 safety score across 53 dividend-paying stocks and ETFs. Here's where ABT lands inside that universe.
The universe is curated to the most-searched US dividend payers. We'll expand it as the data layer grows; sector percentiles only appear when we have at least 5 comparable peers.
The two questions a safety score doesn't answer
A safety score tells you how durable ABT's payout looks. It does not tell you what you keep after tax, or whether something else does the same job better.
On tax: what you actually pocket depends on whether ABT dividends are qualified — qualified distributions are taxed at 0%, 15%, or 20%, while ordinary ones are taxed at your full marginal rate, a gap that can reach 22 percentage points of the income on the same headline yield.
On substitutes: if ABT's 6.8/10 score is lower than you want, see ABT alternatives — same-sector stocks ranked by how closely they match ABT on both yield and safety, so you can see what a swap actually costs you.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
How we score dividend safety
The Infnits dividend safety score is a 0–10 rating derived from yield zone, payout ratio (when applicable), yield trend versus 5-year average, instrument type, and company size. Each factor is independently transparent — see the reasons above for exactly which factors contributed to ABT's score.
For the full methodology including the in-app version that uses ETF look-through and historical cut data, see our methodology page.
This is educational, not investment advice. Dividend safety scores reflect a snapshot of public data on the "as of" date shown. Verify current data on the issuer's investor relations page or your brokerage before making decisions.
Frequently asked questions
Is ABT safe?
On dividend safety specifically, Infnits scores ABT 6.8/10 — solid. Abbott Laboratories has a solid dividend profile with no major red flags in the snapshot data. That score measures how durable the payout looks based on yield zone, payout ratio, yield trend, and instrument type; it does not measure price risk, valuation, or whether ABT suits your portfolio.
Is ABT's dividend safe?
Based on snapshot data — yield 2.39%, payout ratio 79%, instrument type stock — Infnits rates ABT's dividend safety profile as solid (6.8/10). This is one signal, not a recommendation.
What is ABT's current dividend yield?
ABT has a current dividend yield of 2.39% as of September 10, 2026. Its 5-year average yield is 1.82%.
How is ABT's safety score calculated?
The score combines yield zone (yields above 7% historically carry elevated cut risk), payout ratio (lower is safer), trend vs. 5-year average yield, instrument type (ETFs are inherently more diversified), and size (larger companies have more stable cash flows). Each factor is scored 0-2.5 and summed to a 0-10 result.
Where does this data come from?
Fundamentals are sourced from public market data and refreshed regularly. The "as of" date on each page reflects the snapshot used for the score. For real-time data, check the issuer's investor relations page or your brokerage.
Should I buy ABT based on this score?
No — this is an educational score based on a handful of public signals, not investment advice. Use it as one input among many. For a portfolio-aware analysis with ETF look-through and personalized insights, install the Infnits app.
Get emailed when ABT score changes.
ABT head-to-head comparisons
See ABT compared side-by-side with the most-searched peer tickers — yield, safety, growth trend, expense ratio, and tax treatment.
More ABT analysis
Other dividend tickers
See how ABT fits your portfolio
Add your other holdings and the free analyzer shows your total annual income, weighted safety score, and whether ABT is carrying too much of your income. Runs in your browser — no account, no download.
Or read how safety scoring works.